Insmed to present new Phase 3b ENCORE data on ARIKAYCE resistance at IDWeek 2026

INSM•2026-10-14

Insmed said it will present Phase 3b ENCORE findings on antibiotic resistance in newly diagnosed MAC lung disease at IDWeek 2026, alongside other clinical data at CHEST 2026 and IDWeek 2026.

1. Upcoming presentations

Insmed flagged clinical data across TPIP, BRINSUPRI and ARIKAYCE for presentation at CHEST 2026 and IDWeek 2026. IDWeek presentations will include ENCORE findings on antibiotic resistance development in newly diagnosed MAC lung disease, supported by a real-world outcomes analysis.

Insmed to present new Phase 3b ENCORE data on ARIKAYCE resistance at IDWeek 2026

1. Upcoming presentations

Related News

Expedia flags set-jetting as 2027 travel driver, with nearly 1 in 5 travelers booking trips after TV or film exposure

Saudi Aramco headquarters suffered extensive damage in Houthi attack, sources say

Arrowhead climbs on early Alzheimer's drug trial data

Tempest Therapeutics appoints John W. Frederick to board of directors

Matador Resources raises target price to $65 from $59